Orthocell Ltd managing director Paul Anderson talked with Proactive about the company’s strong March quarter and the expanding US opportunity for its nerve repair product Remplir™. Anderson said Orthocell has now moved beyond market access and into active clinical use within the US military and veteran healthcare system, following approval for use across the combined Department of Defense and Department of Veterans Affairs hospital network.
The approval opened access to about 221 hospitals, including 51 military hospitals and 170 VA medical centres, and Anderson described the milestone as important for both the company and the market’s view of its progress. He said the development added significant credibility to the product and its commercial pathway in the US.
Anderson also discussed Orthocell’s readiness to meet rising demand.
For more videos, visit Proactive’s YouTube channel, and don’t forget to like this video, subscribe to the channel and enable notifications for future content.
#Orthocell #ASXOCC #OTCORHHF #PaulAnderson #Remplir #NerveRepair #MedTech #Biotech #USMilitary #VeteransAffairs #DepartmentOfDefense #HealthcareInnovation #SurgicalDevices #AustralianBiotech #USExpansion